Eupraxia Pharmaceuticals Archives

Illustrated CareDx, Regeneron and Eupraxia representatives stand under spotlights with a DNA helix, laboratory flask and syringe, surrounded by digital medical displays and an applauding audience.

CareDx, Regeneron and Eupraxia Put Precision Medicine in the Spotlight -( $CDNA $EPRX $REGN $SNY )

by John F. Heerdink, Jr. 2 hours ago 33Views 0Likes

AlloSure Kidney Data Excites, Dupixent Sales Surge and POTENTIAL Competitor, EP-104GI, Nears December EoE Catalyst Biotechnology’s most persuasive growth stories are moving beyond laboratory promise and into financial statements, clinical evidence and approaching trial milestones. CareDx (NASDAQ: CDNA) reported third-quarter revenue growth…

Illustration of rising oil prices and investors reviewing AI financing costs for the weekly market summary ending October 23, 2026.

Weekly Market Summary, October 23, 2026: Oil Tops $100 as Wall Street Questions AI’s Financing Bill -( $EPRX $MODD $NVDA $SER $SPCX $SKHY $TSLA$MRK $MRNA )

by John F. Heerdink, Jr. October 23, 2026 227679Views 0Likes

NYSE trading floor with screens showing stocks sliding as rising U.S. Treasury yields and Walmart (WMT) earnings pressure risk assets on August 20, 2026.

Scientists in a modern biotechnology laboratory review digital DNA models, molecular structures and drug development charts.

Merck’s $1.3 Billion Silence Deal Puts Precision Biotech in Focus as Serina and Eupraxia Advance -( $BBC $EPRX $IBB $MKKGY $MRK $SER $SLN $XBI )

by John F. Heerdink, Jr. October 19, 2026 370Views 0Likes

A substantial takeover premium highlights the value of differentiated medicines, while Serina Therapeutics and Eupraxia Pharmaceuticals approach clinical milestones of their own. October 19, 2026 Biotechnology investors received a rather emphatic reminder Monday that pharmaceutical innovation can still command a premium, even…

Illustration of a circuit-covered Wall Street bull above a market chasm, beneath an AI brain and inflation tornado, with a $2 trillion label.

Weekly Market Summary – October 16, 2026: Nasdaq Falls 4.5% as AI Jitters, Inflation and a $2 Trillion Deficit Test Wall Street -( $EPRX $MODD $NVDA $SER $SPCX $TRV $TSLA )

by John F. Heerdink, Jr. October 16, 2026 181527Views 0Likes

NYSE trading floor with screens showing stocks sliding as rising U.S. Treasury yields and Walmart (WMT) earnings pressure risk assets on August 20, 2026.

Eupraxia Pharmaceuticals illustration showing a dart hitting a 120-patient enrollment target, a December data calendar, and the EPRX stock ticker.

Eupraxia Pharmaceuticals Hits RESOLVE Enrollment Target as December EoE Data Come Into Focus -( $EPRX $XBI $IBB )

by John F. Heerdink, Jr. October 16, 2026 461Views 0Likes

With 120 patients enrolled in its Phase 2b study, Eupraxia’s drug-delivery platform moves toward a consequential clinical test. For Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX; TSX: EPRX), the story is becoming less about recruiting patients and more about what their results might reveal.…

Vintage comic-style illustration of three bulls pulling a loaded wagon through sunny farmland, with “EPRX” and “Trio of Bulls” above.

Eupraxia: Three Bullish Analyst Reports Put EP-104GI’s EoE Opportunity in Focus Post Tezspire Results -( $AMGN $APGE $AZN $EPRX $REGN $SNY $TAK )

by John F. Heerdink, Jr. October 12, 2026 644Views 0Likes

Wall Street Price targets of $16, $17 and $18 seem to underscore the potential for a long-acting treatment as December clinical data approach Eupraxia Pharmaceuticals (NASDAQ: EPRX; TSX: EPRX) has received a timely vote of confidence from three research firms, with newly…

October 9, 2026 weekly market summary illustration showing rising stock charts, AI servers, and declining consumer sentiment bars

Weekly Market Summary (Friday, October 9, 2026): Stocks Close Higher as AI Rebounds and Consumer Sentiment Weakens -( $AMWL $DAL $DOCS $EPRX $LITE $LLY $LPL $MODD $MRNA $NVDA $SER $TSLA $YSG )

by John F. Heerdink, Jr. October 9, 2026 158250Views 0Likes

NYSE trading floor with screens showing stocks sliding as rising U.S. Treasury yields and Walmart (WMT) earnings pressure risk assets on August 20, 2026.

Comic-book-style illustration highlighting pharma, space and AI investment themes: a Bayer research lab in Ohio, a SpaceX rocket launching from an Ohio-inspired Starbase, and Eupraxia displayed over an AI-powered global network, beneath the headline “Pharma, Rockets and AI: Why Bayer, SpaceX and Eupraxia Have Investors Looking Up.”

Pharma, Rockets and AI: Why Bayer, SpaceX and Eupraxia Have Investors Looking Up -( $BAYRY $EPRX $GOOGL $SPCX $TSLX )

by John F. Heerdink, Jr. October 3, 2026 400Views 0Likes

The Market’s Growth Engines Are Getting Physical Wall Street has spent years rewarding promises around artificial intelligence, advanced medicine and space infrastructure. This week, the narrative acquired something investors usually appreciate even more: concrete evidence of execution. Bayer AG (OTC: BAYRY) is…

Business analysts review Eupraxia Pharmaceuticals’ EP-104GI clinical data, including symptom reduction and histological-response visuals, alongside an investment calendar highlighting the anticipated December 2026 RESOLVE trial milestone.

Eupraxia’s One-Year EoE Data Draw Fresh Analyst Attention Ahead of December Catalyst – ( $EPRX $IBB $SNY $XBI )

by John F. Heerdink, Jr. October 2, 2026 785Views 0Likes

Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX; TSX: EPRX) has added a new layer of clinical durability to its EoE investment case, and Wall Street’s bullish coverage is becoming harder to overlook. The company’s latest 52-week EP-104GI data, including 64% clinical remission among evaluable higher-dose…

Promotional graphic for a Tribe Public CEO dinner event featuring Eupraxia Pharmaceuticals (NASDAQ: EPRX), James Helliwell, M.D., and the company’s 52-week EP-104GI clinical update for eosinophilic esophagitis. The image illustrates localized treatment at week zero, durable symptom control through week 52, and a stylized upward EPRX market graphic.

Eupraxia’s One-and-Done EoE Strategy Gains a 52-Week Tailwind -( $EPRX $IBB $REGN $SNY $XBI )

by John F. Heerdink, Jr. September 30, 2026 480Views 0Likes

Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX; TSX: EPRX) has added a potentially important chapter to its eosinophilic esophagitis, or EoE, story: a single administration of its investigational localized therapy, EP-104GI, continued to show clinical-remission signals at 52 weeks in the highest-dose cohorts of the…

Tag: Eupraxia Pharmaceuticals

CareDx, Regeneron and Eupraxia Put Precision Medicine in the Spotlight -( $CDNA $EPRX $REGN $SNY )

Weekly Market Summary, October 23, 2026: Oil Tops $100 as Wall Street Questions AI’s Financing Bill -( $EPRX $MODD $NVDA $SER $SPCX $SKHY $TSLA$MRK $MRNA )

Merck’s $1.3 Billion Silence Deal Puts Precision Biotech in Focus as Serina and Eupraxia Advance -( $BBC $EPRX $IBB $MKKGY $MRK $SER $SLN $XBI )

Weekly Market Summary – October 16, 2026: Nasdaq Falls 4.5% as AI Jitters, Inflation and a $2 Trillion Deficit Test Wall Street -( $EPRX $MODD $NVDA $SER $SPCX $TRV $TSLA )

Eupraxia Pharmaceuticals Hits RESOLVE Enrollment Target as December EoE Data Come Into Focus -( $EPRX $XBI $IBB )

Eupraxia: Three Bullish Analyst Reports Put EP-104GI’s EoE Opportunity in Focus Post Tezspire Results -( $AMGN $APGE $AZN $EPRX $REGN $SNY $TAK )

Weekly Market Summary (Friday, October 9, 2026): Stocks Close Higher as AI Rebounds and Consumer Sentiment Weakens -( $AMWL $DAL $DOCS $EPRX $LITE $LLY $LPL $MODD $MRNA $NVDA $SER $TSLA $YSG )

Pharma, Rockets and AI: Why Bayer, SpaceX and Eupraxia Have Investors Looking Up -( $BAYRY $EPRX $GOOGL $SPCX $TSLX )

Eupraxia’s One-Year EoE Data Draw Fresh Analyst Attention Ahead of December Catalyst – ( $EPRX $IBB $SNY $XBI )

Eupraxia’s One-and-Done EoE Strategy Gains a 52-Week Tailwind -( $EPRX $IBB $REGN $SNY $XBI )

Your Guide To Staying Informed In The Markets